Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of Staphylococcus aureus

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 10, 2003, Pages 1745-1749

  Kerns, Robert J ^a   Rybak, Michael J ^b   Kaatz, Glenn W ^c   Vaka, Flamur ^b   Cha, Raymond ^b   Grucz, Richard G ^b   Diwadkar, Veena U ^b   Ward, Tracey D ^b  

^a UNIVERSITY OF IOWA   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DIMER; DNA TOPOISOMERASE IV; NORFLOXACIN; PIPEMIDIC ACID; PIPERAZINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASYMMETRIC SYNTHESIS; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; GENE MUTATION; MULTIDRUG RESISTANCE; NONHUMAN; STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS AUREUS;

EID: 0038702176     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00208-7     Document Type: Article

References (27)

1. (a) . The following are selected reviews on FQ mechanism of action and clinical applications. Hooper D.C. Biochem. Biophys. Acta. 1400:1998;45
2. (b) Drlica K. Curr. Opin. Microbiol. 2:1999;504
3. (c) Hooper D. Drugs. 58:1999;6
4. (d) Gootz T., Brighty K. Med. Res. Rev. 16:1996;433
5. (e) Bhanot S., Singh M., Chatterjee N. Curr. Pharm. Des. 7:2001;311.
6. (a) Hooper D.C. Emerg. Infect. Dis. 7:2001;337
7. (b) Acar J. Clin. Inf. Dis. 24:1997;S67.
8. Drlica K., Zhao X. Microbiol. Mol. Biol. Rev. 61:1997;377.
9. Morais Cabral J., Jackson A., Smith C., Shikotra N., Maxwell A., Liddington R. Nature. 388:1997;903.
10. (a) Markham P.N., Neyfakh A.A. Curr. Opin. Microbiol. 4:2001;509
11. (b) Poole K. Antimicrob. Agents Chemother. 44:2000;2595
12. (c) Poole K. Antimicrob. Agents Chemother. 44:2000;2233.
13. (a) Yu J.-L., Grinius L., Hooper D.C. J. Bacteriol. 184:2002;1370
14. (b) Kaatz G., Seo S. Antimicrob. Agents Chemother. 41:1997;2733
15. (c) Kaatz G., Seo S. Antimicrob. Agents Chemother. 39:1995;2650
16. (d) Kaatz G., Seo S., O'Brien L., Wahiduzzaman M., Foster T. Antimicrob. Agents Chemother. 44:2000;1404.
17. (a) Markham P.N. Antimicrob. Agents Chemother. 43:1999;988
18. (b) Markham P.N., Neyfakh A.A. Antimicrob. Agents Chemother. 40:1996;2673.
19. Kerns, R. J.; Vaka, F.; Grucz, R. G.; Kaatz, G. W.; Rybak, M. J.; Cha, R.; Diwadkar, V. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; American Society for Microbiology: Washington, DC, 2001; Abstract F-565.
20. 1H NMR, mass spectroscopic analysis and analytical HPLC showing a single peak at 220 nm and 254 nm.
21. Ng E., Trucksis M., Hooper D. Antimicrob. Agents Chemother. 40:1996;1881.
22. MICs were determined by broth microdilution following NCCLS guidelines using 2-fold dilutions of test compound. Error for MICs is therefore±one dilution.
23. The symmetric norfloxacin dimers do not interfere with NorA-mediated efflux of ethidium bromide in SA 1199-B at concentrations up to five times the MIC. (Data not shown, see ref 6d for a description of this assay.) Therefore it is unlikely that the dimers are substrates for the NorA pump, accounting for their ability to evade this efflux mechanism.
24. Coppel R., Deady L., Loria P., Olden D., Turnidge J. Aust. J. Chem. 49:1996;255.
25. Lee S.-P., Im C., Kim D.-S., Yim C.-B. J. Pharm. Soc. Korea (Yakhak Hoeji). 38:1994;664.
26. Fatheree, P.; Pace, J. L.; Judice, J. K.; Griffin, J. H. WO Patent 9964051, 1999; Chem. Abstr. 1999, 132, 35622.
27. Shen L., Mitscher L., Sharma P., O'Donnel T., Chu D., Cooper C., Rosen T., Pernet A. Biochemistry. 28:1989;3886.